Diaxonhit forms biotech deals by entering into a research service agreement with big pharma Boehringer Ingelheim for the discovery and characterization of novel splice variants that have the potential to be therapeutic targets for oncology.
Through the agreement Boehringer Ingelheim secures an option to acquire the rights to research, develop and commercialize, any targets identified using Diaxonhit’s patented SpliceArray discovery platform, with the aim of adding further to its comprehensive research programme to develop innovative new cancer drugs.
Diaxonhit will apply its expertise and target discovery platform, built upon its genome-wide SpliceArray technology, to identify splice variants that are expressed in cancer tissue.
These variants will be analyzed using a unique workflow tailored to rapidly identify and characterize novel epitope targets suitable for antibody-based therapeutic development.
Financial terms were not disclosed.
For further deal information visit Current Agreements (subscription required)
Read: more on Boehringer Ingelheim company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Baxter Healthcare
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity